Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
TTX-MC138
product2 mentionslast seen Oct 28, 2026
Novel anti-miR-10b therapeutic candidate for advanced solid tumors.
Relationships 6
- Transcode Therapeutics, Inc.developsTTX-MC13899% confidence2 sources
- TTX-MC138depends onmicroRNA-10b inhibition93% confidence1 source
- TTX-MC138implementsmicroRNA-10b inhibition92% confidence1 source
- TTX-MC138applies tometastatic cancer treatment90% confidence1 source
- TTX-MC138applies tometastatic colorectal cancer treatment88% confidence1 source
- TTX-MC138applies tocolorectal cancer treatment88% confidence1 source
Relationship
Transcode Therapeutics, Inc.developsTTX-MC138
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 28, 2026Transcode Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers, today announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities designed to maximize the value of the Company and its oncology portfolio, including its lead product candidate, TTX-MC138
- filingSEC EDGARSep 28, 2026Transcode Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
TTX-MC138, its novel anti-miR-10b therapeutic candidate